La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Tevogen Bio Holdings a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Tevogen Bio Holdings..

Tevogen Bio Holdings (NASDAQ:TVGN) Azioni, Catena delle Opzioni

Tevogen Bio Holdings

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Tevogen Bio Holdings Inc

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>Name</strong></th>
<th align="right"><strong>Price</strong></th>
<th align="right"><strong>Change ($)</strong></th>
<th align="right"><strong>Change (%)</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">43.94</td>
<td align="right">0.18</td>
<td align="right">0.41</td>
<td>2.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">82.21</td>
<td align="right">0.32</td>
<td align="right">0.39</td>
<td>14.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">144.40</td>
<td align="right">0.37</td>
<td align="right">0.25</td>
<td>1.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">215.27</td>
<td align="right">0.27</td>
<td align="right">0.12</td>
<td>183</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">50.22</td>
<td align="right">0.05</td>
<td align="right">0.09</td>
<td>234.5K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>Name</strong></th>
<th align="right"><strong>Price</strong></th>
<th align="right"><strong>Change ($)</strong></th>
<th align="right"><strong>Change (%)</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">97.00</td>
<td align="right">-0.12</td>
<td align="right">-0.13</td>
<td>9.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">81.06</td>
<td align="right">-0.03</td>
<td align="right">-0.04</td>
<td>858</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">233.43</td>
<td align="right">-0.05</td>
<td align="right">-0.03</td>
<td>21.7K</td>
</tr>
</tbody>
</table>
<p><a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> the above sector movers alert assists traders in understanding macro-level trends and market variations. Traders will look for sector movers providing information on sectors that are over- or under-performing, deriving these results into investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. </p>
<p><em>For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.</em> </p>


Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For November 22, 2024

<p>Targeting $200B Digital Grocery Market With Key Retailers Like Fareway Stores And Vroom Delivery</p>


News

PUBM

PubMatic Partners With DIGITS Agency To Monetize Digital Grocery Advertising Through Scalable AdTech Platform

<p>Wells Fargo  analyst Gary Mobley   initiates coverage on Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) with a Overweight rating and announces Price Target of $23.</p>


Price Target

Initiation

Analyst Ratings

ALGM

Wells Fargo Initiates Coverage On Allegro Microsystems with Overweight Rating, Announces Price Target of $23

<p>Leerink Partners  analyst Jeffrey La Rosa   initiates coverage on Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) with a Outperform rating and announces Price Target of $79.</p>


JANX

Leerink Partners Initiates Coverage On Janux Therapeutics with Outperform Rating, Announces Price Target of $79

<p>Keybanc  analyst Tim Rezvan   maintains Gulfport Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>) with a Overweight and raises the price target from $165 to $205.</p>


GPOR

Keybanc Maintains Overweight on Gulfport Energy, Raises Price Target to $205

WIIM

APTO

Aptose Biosciences shares are trading lower after the company announced the pricing of an $8 million public offering.

Offerings

Aptose Biosciences Prices $8M Public Offering Of 40M Shares And 20M Warrants At $0.20 Per Unit; Warrants Priced At $0.25 Per Share And Expire In Five Years, With Closing Expected On November 25, 2024

<p>Goldman Sachs  analyst Adam Bubes   initiates coverage on AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) with a Buy rating and announces Price Target of $130.</p>


Goldman Sachs Initiates Coverage On AECOM with Buy Rating, Announces Price Target of $130

<p>Wells Fargo  analyst Joe Quatrochi   initiates coverage on ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Overweight rating and announces Price Target of $155.</p>


Wells Fargo Initiates Coverage On ARM Holdings with Overweight Rating, Announces Price Target of $155

SBFM

Sunshine Biopharma shares are trading higher after its Nora Pharma subsidiary launched Ursodiol, a generic version of URSO DS.

<p>Keybanc  analyst Steve Barger   maintains AMETEK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>) with a Overweight and raises the price target from $205 to $215.</p>


Keybanc Maintains Overweight on AMETEK, Raises Price Target to $215

<p>Confirmed By Nasdaq Listing Qualifications On November 21, 2024</p>


NDRA

ENDRA Life Sciences Regains Compliance With Nasdaq Minimum Bid Price Rule

Sunshine Biopharma's Nora Pharma Subsidiary Launches Ursodiol, A Generic Version Of URSO DS

<p>Goldman Sachs  analyst Adam Bubes   initiates coverage on EMCOR Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>) with a Sell rating and announces Price Target of $445.</p>


Goldman Sachs Initiates Coverage On EMCOR Group with Sell Rating, Announces Price Target of $445

<p>UBS  analyst David Vogt   initiates coverage on Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Neutral rating and announces Price Target of $95.</p>


UBS Initiates Coverage On Celestica with Neutral Rating, Announces Price Target of $95

<p>Goldman Sachs  analyst Ben Andrews   initiates coverage on Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy rating and announces Price Target of $320.</p>


FLUT

Goldman Sachs Initiates Coverage On Flutter Entertainment with Buy Rating, Announces Price Target of $320

Nano Labs Unveils Second-Generation V Series Crypto Mining Products With 5x Power Efficiency Boost And Enhanced Stability, Featuring Advanced Cuckoo 3.0 Chips In V2, V2H, And V2X Models

Applied Industrial Technologies To Acquire Hydradyne, Terms Not Disclosed; Applied Expects The Acquisition To Contribute Approximately $260M In Sales And $30M In EBITDA Before Anticipated Synergies

Biotech

General

HUMA

Humacyte To Present Phase 3 Results Comparing Efficacy And Safety Of Tissue-Engineered Vessel To AV Fistulas In End-Stage Renal Disease Patients At VEITH Symposium On November 23, 2024

Johnson & Johnson Submits Supplemental Biologics License Application To FDA Seeking Approval Of Subcutaneous Induction Regimen Of TREMFYA

Tevogen Bio, Rani Therapeutics, and Expion360 are the 3 Penny Stocks to watch on October 15, 2024, based on&nbsp;TipRanks' Penny Stock Screener too...

3 Penny Stocks to Watch Now, 10/15/24

Tevogen (TVGN) Bio reported last week that Chief Scientific Officer Dr. Neal Flomenberg sold shares. "Tevogen's Chief Financial Officer, Kirti Desa...

Tevogen says CSO share sale 'solely' to satisfy payment of tax obligations

Tevogen Bio (TVGN) announces its Artificial Intelligence effort, Tevogen AI, has joined Microsoft (MSFT) for Startups. This partnership marks a sig...

Tevogen AI joins Microsoft for Startups

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: McDonald's (MCD) shares are continuing...

McDonald's down after outbreak, Starbucks slides after warning: Morning Buzz

Tevogen (TVGN) Bio provided additional guidance on the first clinical product of the company's proprietary ExacTcell technology, TVGN 489, designed...

Tevogen provides more guidance on ExacTcell technology

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Boeing (BA) will offer 90M shares of c...

Boeing to offer 90M common shares, Philips reports mixed Q3: Morning Buzz

Tevogen (TVGN) announced that it received written notice from the Listing Qualifications Staff of Nasdaq stating that the company has regained comp...

Tevogen regains compliance with Nasdaq

Tevogen Bio (TVGN) announced its Artificial Intelligence effort, Tevogen.AI, had partnered with Microsoft (MSFT) (MSFR) Using Microsoft's suite of ...

Tevogen leverages Microsoft partnership to deliver target identification for HPV

Tevogen Bio Holdings reports Q3 results

Kirti Desai, CPA, Tevogen's (TVGN) CFO, commented, "The company is in a unique position as it relates to reporting intangible assets on our balance...

Tevogen reports Q3 EPS (3c) vs (3c) last year

AAPL

ARLP

COIN

CORZ

CPAY

CSTM

EBAY

ENPH

EQNR

GLUE

GOOG

GOOGL

INTC

MSFT

NPPXF

NTTYY

PRCT

RANI

REAL

SAVE

SBUX

SNAP

TVGN

ULCC

XPON

Press Releases

Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company

Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs

Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

Management

Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company's Novel Business Model as Key to Sustainable Success through Patient Affordability

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Earnings

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value

Comments

Tevogen Bio Holdings

Tevogen Bio Holdings (TVGN) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO